What are the side effects of Relugolix?

In clinical studies of Relugolix, the most common adverse reactions (≥10%) and laboratory abnormalities (≥15%) were hot flashes, increased glucose, increased triglycerides, musculoskeletal pain, decreased hemoglobin, increased alanine aminotransferase (ALT), fatigue, aspartate Elevated acid aminotransferase (AST), constipation and diarrhea;There have also been warnings and precautionsQT/QTc interval prolongation, allergic reactions, embryo-fetal toxicity; allergies, including angioedema, urticaria and other adverse events have occurred after Regaglic was put on the market.

Serious adverse reactions include myocardial infarction, acute kidney injury, cardiac arrhythmias, bleeding, and urinary tract infection. Fatal adverse reactions, including metastatic lung cancer, myocardial infarction, and acute kidney injury, occurred in 0.8% of patients who received Repagliflox. Fatal and nonfatal myocardial infarction and stroke were reported in 2.7% of patients receiving Repagliflozin. 3.5% of patients permanently discontinued repagliflozin due to adverse reactions, including atrioventricular block, heart failure, bleeding, elevated aminotransferases, abdominal pain, and pneumonia. 2.7% of patients had their dose of repagliflox discontinued due to adverse reactions, including fractures.

The original drug of Regogliflox has not yet been launched in the country, so it is not covered by medical insurance. There are European and Japanese versions of the original drug Rleglik available overseas. The ingredients of the two are basically the same. The price of the European version of 120mg*30 tablets per box may be around RMB 4,000, and the price of the Japanese version of 40mg*100 tablets per box may be around RMB 4,000 (the price may fluctuate due to exchange rates). Currently, there are no generic versions of Repagliflox produced and put on the market.